CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 20 enrolled
Drug / intervention
L-ascorbic aciddrug
Likely dose
L-ascorbic acid 50 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04357782
NCT04357782Phase 2Completed
CompareCT.gov

Administration of Intravenous Vitamin C in Novel Coronavirus Infection and Decreased Oxygenation (AVoCaDO): A Phase I/II Safety, Tolerability, and Efficacy Clinical Trial

Hunter Holmes Mcguire Veteran Affairs Medical Center·interventional·Posted Apr 22, 2020·Updated Feb 25, 2022

In Brief

A Phase 2 clinical trial evaluating L-ascorbic acid for COVID-19 and Hypoxia. Completed, enrolled 20 participants across 1 site.

Detailed Summary

Previous research has shown that high dose intravenous vitamin C (HDIVC) may benefit patients with sepsis, acute lung injury (ALI), and the acute respiratory distress syndrome (ARDS). However, it is not known if early administration of HDIVC could prevent progression to ARDS. We hypothesize that HDIVC is safe and tolerable in Coronavirus disease 2019 (COVID-19) subjects given early or late in the disease course and may reduce the risk of respiratory failure requiring mechanical ventilation and development of ARDS along with reductions in supplemental oxygen demand and inflammatory markers.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCOVID-19, Hypoxia
CountriesUnited States
CollaboratorsMcGuire Research Institute

Timeline

Phase 2CompletedFinished
202120222023202420252026
First PostedApr 22, 2020
Enrollment StartApr 16, 2020
Primary CompletionOct 13, 2020
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 6.2 years ago

Interventions

L-ascorbic aciddrug

50 mg/kg L-ascorbic acid infusion given every 6 hours for 4 days (16 total doses)